Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
gains, 14 products topping $1B and 18 achieving record sales, driven by six growth pillars including Repatha, Tezspire, rare disease, innovative oncology (BiTE) and biosimilars. Rare disease — UPLIZNA surge: UPLIZNA sales rose 73% in 2025 after the IgG4-related disease launch and a gMG approval, and Amgen plans additional Phase III studies in autoimmune hepatitis and CIDP to expand indications. Pipeline & oncology focus: Amgen's BiTE platform is gaining traction (IMDELLTRA now a 2L+ SCLC standard with multiple Phase III studies) while MariTide advances in six global Phase III trials for obesity, emphasizing monthly/quarterly dosing to boost adherence and long-term persistence. Interested in Amgen Inc.? Here are five stocks we like better. Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference s
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- 4 Biotech Stocks to Watch for Potential Upside in 2026 [Yahoo! Finance]Yahoo! Finance
- Two major drug companies are the latest to join TrumpRx [FOX Business Network]FOX Business Network
- Rapid Micro Biosystems Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Amgen (AMGN) is now covered by Jefferies Financial Group Inc.. They set a "hold" rating and a $350.00 price target on the stock.MarketBeat
AMGN
Earnings
- 2/3/26 - Beat
AMGN
Sec Filings
- 3/6/26 - Form 4
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- AMGN's page on the SEC website